Thursday March 11, 7:31 am Eastern Time
HOUSTON--(BUSINESS WIRE)--March 11, 1999--Pathobiotek Diagnostics, Inc.,
a developer of diagnostic products for the
treatment of multiple sclerosis (MS) and other immune disorders, today announced the Company has launched a new web site. www.pathobiotek.com provides current news releases and Company information for the investor and medical communities.
"This sophisticated, user-friendly and high-end web site will help further Pathobiotek's overall recognition," stated Robert Simpson, President and CEO of Pathobiotek. "Additionally, we intend to use the website as an information center for our shareholders, customers and collaborators. Information will be upgraded more frequently than in the past allowing the reader to view the Company's progress as the news becomes available. A non-confidential product brochure will be available soon, as well as a more complete picture of our technology."
Pathobiotek is a research and development Biotechnology Company dedicated to developing, producing and licensing diagnostics for multiple sclerosis (MS) and other immune disorders.
Safe Harbor Statement: Except for historical information contained herein, the matters set forth in this news release are forward-looking statements. Forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those identified in the Company's filings with the Securities and Exchange Commission.
DeMonte Associates, New York
Cynthia DeMonte, 212/473-3700
Copyright © 1999 Business Wire. All rights reserved.